Deeming Duravyu’s path forward in diabetic macular edema “very viable” after Monday's data drop, analyst Graig Suvannavejh, Ph.D., said Mizuho Securities considers EyePoint's drug-device combo a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results